BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel PM, Jones VA, Kridin K, Amber KT. The role of Dipeptidyl Peptidase-4 in cutaneous disease. Exp Dermatol 2021;30:304-18. [PMID: 33131073 DOI: 10.1111/exd.14228] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Fang H, Xue K, Cao T, Li Q, Dang E, Liu Y, Zhang J, Qiao P, Chen J, Ma J, Shen S, Pang B, Bai Y, Qiao H, Shao S, Wang G. CXCL12/CXCR4 Axis Drives the Chemotaxis and Differentiation of B Cells in Bullous Pemphigoid. J Invest Dermatol 2023;143:197-208.e6. [PMID: 36075452 DOI: 10.1016/j.jid.2022.08.041] [Reference Citation Analysis]
2 Tuusa J, Kokkonen N, Mattila A, Huilaja L, Varpuluoma O, Rannikko S, Glumoff V, Miettunen J, Tasanen K. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin. J Invest Dermatol 2023;143:78-86.e12. [PMID: 35921900 DOI: 10.1016/j.jid.2022.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hui Y, Xu Z, Li J, Kuang L, Zhong Y, Tang Y, Wei J, Zhou H, Zheng T. Nonenzymatic function of DPP4 promotes diabetes-associated cognitive dysfunction through IGF-2R/PKA/SP1/ERp29/IP3R2 pathway-mediated impairment of Treg function and M1 microglia polarization. Metabolism 2023;138:155340. [PMID: 36302455 DOI: 10.1016/j.metabol.2022.155340] [Reference Citation Analysis]
4 Jones L, Jones AM. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? Pharmacol Res Perspect 2022;10:e01029. [PMID: 36468400 DOI: 10.1002/prp2.1029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hung CT, Chang YL, Wang WM. Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis. Int J Mol Sci 2022;23. [PMID: 36430582 DOI: 10.3390/ijms232214101] [Reference Citation Analysis]
6 Lee CH, Huang SC, Hung KC, Cho CJ, Liu SJ. Enhanced Diabetic Wound Healing Using Electrospun Biocompatible PLGA-Based Saxagliptin Fibrous Membranes. Nanomaterials (Basel) 2022;12. [PMID: 36364516 DOI: 10.3390/nano12213740] [Reference Citation Analysis]
7 Opelka B, Schmidt E, Goletz S. Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders. Front Immunol 2022;13:948108. [DOI: 10.3389/fimmu.2022.948108] [Reference Citation Analysis]
8 Nätynki A, Leisti P, Tuusa J, Varpuluoma O, Huilaja L, Izumi K, Herukka S, Ukkola O, Junttila J, Kokkonen N, Tasanen K. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients. Front Immunol 2022;13:942131. [DOI: 10.3389/fimmu.2022.942131] [Reference Citation Analysis]
9 Jones L, Jones AM. Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?. [DOI: 10.1101/2022.06.30.22277085] [Reference Citation Analysis]
10 Iwamoto Y, Anno T, Koyama K, Kawasaki F, Kaku K, Tomoda K, Sugiyama S, Aoyama Y, Kaneto H. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Front Immunol 2022;13:843480. [PMID: 35309321 DOI: 10.3389/fimmu.2022.843480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Quaglino P, Novelli M, Fava P, Ortolan E, Astrua C, Tonella L, Tomasini CF, Senetta R, Ribero S, Ponti R, Fierro MT, Funaro A, Nicolazzo C. CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/3424413] [Reference Citation Analysis]
12 Nieto-Benito LM, Bergón-Sendín M, Pulido-Pérez A, Suárez-Fernández RM. Clinical outcome and safety profile of rituximab for the treatment of Dipeptidyl peptidase 4 inhibitors-induced Bullous pemphigoid. Exp Dermatol 2021. [PMID: 34695279 DOI: 10.1111/exd.14483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Huang X, Khoong Y, Han C, Su D, Ma H, Gu S, Li Q, Zan T. Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity? Front Physiol 2021;12:694605. [PMID: 34335301 DOI: 10.3389/fphys.2021.694605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Solimani F, Didona D, Li J, Bao L, Patel PM, Gasparini G, Kridin K, Cozzani E, Hertl M, Amber KT. Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS. Arch Dermatol Res 2021. [PMID: 34152480 DOI: 10.1007/s00403-021-02253-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bao L, Li J, Perez White BE, Patel PM, Amber KT. Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes. Arch Dermatol Res 2021. [PMID: 34089377 DOI: 10.1007/s00403-021-02249-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]